tbuckley/cabot-search huggingface dataset:
Abstract 2427: Endothelioma of bone revisited: G-Protein coupled receptor 64 promotes invasiveness and metastasis in Ewing Tumors
Authors: Günther H. Richter, Annette Fasan, Sabine Roessler, Stefan Burdach
Journal: Cancer Research (2011)

Abstract Metastatic spread in Ewing Tumors (ET) is frequent and hematogenous. Microarray analysis revealed the G-protein coupled receptor 64 (GPR64), an orphan receptor with normal expression restricted to human epididymis, to be over-expressed in ET. Members of this family of receptors have been implicated with vascularization and neuronal development. Inhibition of GPR64 expression by RNA interference impaired endothelial differentiation in vitro and suppressed local tumor growth and metastasis in Rag2-/-γC-/- mice. Microarray analysis of ET after GPR64 knock down revealed a GPR64-mediated suppression of genes involved in differentiation like v-erb-a erythroblastic leukemia viral oncogene homolog 4 (ERBB4), and genes stimulating transcriptional activation including pre-B cell leukemia homeobox 2 (PBX2) and SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4 (SMARCA4). Similarly, a GPR64-mediated induction of VEGF receptor 1 ligand placental growth factor (PGF) in ET was observed. PGF itself was induced by EWS-FLI1 in mesenchymal stem cells. The GPR64-mediated induction of placental growth factor (PGF) and repression of PGF resulted in a phenotype similar observed after GPR64 knockdown. GPR64 as well as PGF inhibition was associated with reduced proteolytic activity of Matrix Metalloproteinase (MMP) 1 and invasiveness in vitro. MMP1 knock down abrogated lung metastasis in Rag2-/-γC-/- mice. GPR64 and subsequent up-regulation of PGF and MMP1 orchestrate and promote invasiveness and metastatic spread of this tumor, and provide significant conceptual progress in understanding both the histogenesis of ET in particular and the pathogenesis of metastatic dispersal in general. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 2427. doi:10.1158/1538-7445.AM2011-2427
AB0707 Hip Joints Involvement in Ankylosyng Spondylitis: Ultrsosnography VS Clinical Examination
Authors: M. Podryadnova, R. Balabanova, M. Urumova, A. Bochkova, M. Severinova, S. Erdes
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Hip joints involvement in AS pts detected in 46% in Russia, in 7% it leads to arthroplasty. <h3>Objectives</h3> To compare ultrasonography data with clinical manifestation of hip area involvment in AS patients <h3>Methods</h3> We studied 160 consecutively hospitalized AS pts. Mean age in our cohort was 35,0±9,1, mean age of disease onset 30,6±11,0. HLA-B27 was detected in 82%pts. Mean BASDAI was 4,5±2,1, ASDAS - 3,3±1,2, BASFI - 4,4±2,6. All patients were examined clinically. In all pts hip joints examined sonographically on Sono Diagnost 360 (Philips) with linear (7,5 MHz) and convex (5,0 MHz) transducers. Synovitis of the hip joint were measured in the space between the femoral neck and the joint capsule, the so-called synovial joint space (SJS).An SJS of more than 7mm was recorded as indicative of synovitis. <h3>Results</h3> US synovitis in hip joints was detected in 82 (51%) pts, 70 (85%) of them reported of pain or function decrease in hip joints. 12 (15%) pts have no clinical manifestation of join involvement. There was no difference in mean age between these groups. Mean disease duration was significantly higher in pts with synovitis. From 78 pts with no synovitis, 51 was complained of pain. 42 (82%) of these pts has US evidenced trochanteritis and enthesitis of pelvis area. 27 pts from 160 have no clinical or US symptoms of hip joint involvement. <h3>Conclusions</h3> In AS pts pain in the hip joints could be a clinical manifestation not only synovitis, but also enthesis inflammation. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.4007
Developments in Rotary Abrasive Technics for Removing Acne Scars and Other Cosmetic Defects
Authors: Joseph J. Eller
Journal: New England Journal of Medicine (1955)

THE high-speed rotary abrasive technic has proved to be the most efficient procedure for removing pitted scars from acne, furuncles and smallpox, as well as those from certain traumas, and also for the removal of tattoos, pigmentations, certain nevi, keratoses and rhinophymas. For these cases the following different types of rotary abrasives have been used: heatless stones, steel burrs, steel-wire brushes and diamond and ruby fraises powered by high-speed rotary motors.The recent improvements in apparatus and technics, combined with the use of the newer local anesthetics, have made this method simple and safe. No hospitalization is required, and the . . .
THE IMPACT OF AGE AND COMPLETION OF A MODERATE DISTANCE RUNNING RACE ON CARDIAC FUNCTION: RESULTS FROM P.E.A.C.H. (PROFILING THE EFFECTS OF AGING ON EXERCISE-INDUCED CHANGES IN CARDIAC MECHANICS)
Authors: Jonathan H. Kim, Yi-An Ko, Mosaab Awad, Jeff Hedley, James Macnamara, William Taylor, Sean Healy, Hiroshi Aida, Anh Le, Melissa White, Peter Wilson, Joseph Wilson, Laurence Sperling, Aaron Baggish
Journal: Journal of the American College of Cardiology (2016)
Dissociation of Voluntary and Emotional Innervation after Stroke
Authors: Ludwig Kappos, Matthias Mehling
Journal: New England Journal of Medicine (2010)

A 72-year-old man presented with a sudden onset of slurred speech. His medical history was unremarkable, and he was taking no medications and did not smoke. The physical examination revealed left-sided facial paralysis and dysarthrophonia. Diffusion-weighted magnetic resonance imaging showed a hyperintensity in the right precentral gyrus, reflecting acute cerebral ischemia (Panel A, arrow). Three days after the stroke, the patient showed impaired voluntary innervation. When he was asked to smile on command, he was unable to fully smile because of facial paralysis on the left side (Panel B). However, during emotional encounters, the patient was able to overcome . . .
P817 EARLY MENOPAUSAL STATUS IS ASSOCIATED WITH THE SEVERITY OF LIVER FIBROSIS IN ITALIAN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE
Authors: S. Petta, E. Vanni, L. Valenti, L. Miele, M. Bianchini, A.L. Fracanzani, E. Bugianesi, A. Craxì, S. Fargion, A. Grieco, C. Cammà, E. Villa
Journal: Journal of Hepatology (2014)
USEFULNESS OF ULTRASOUND-GUIDED FEMORAL VEIN ACCESS IN ATRIAL FIBRILLATION ABLATION
Authors: Carola Gianni, Carlos Monreal, Chintan Trivedi, Sanghamitra Mohanty, Yalçın Gökoğlan, Mahmut F. Güneş, Rong Bai, Amin Al-Ahmad, J. David Burkhardt, G. Joseph Gallinghouse, Rodney P. Horton, Patrick M. Hranitzky, Javier E. Sanchez, Luigi Di Biase, Andrea Natale
Journal: Journal of the American College of Cardiology (2016)
Abstract 2190: cIAP2 as a therapeutic target in malignancies.
Authors: Koh Miura, Hideaki Karasawa, Wataru Fujibuchi, Shinobu Ohnuma, Michiaki Unno
Journal: Cancer Research (2013)

Abstract [Introduction] Inhibition of the apoptotic pathway is one of the factors that may be responsible for carcinogenesis and drug resistance, and the inhibitor of apoptosis protein (IAP) family is thought to prevent apoptosis through inhibition of caspases and pro-caspases and may affect anti-cancer drug sensitivity. [Purposes] The purpose of this study is to clarify the roles of cellular inhibitor of apoptosis 2 (cIAP2) gene, which is a member of IAP family, on apoptosis and 5-FU sensitivity in cancer cells. [Methods and Results] The expression profiles of human colon cancer cell line DLD-1, its 5-FU-resistant subclone DLD-1/FU and further 21 types of colon cancer cell lines were compared. 50% inhibitory concentration (IC50) of 5-FU in DLD-1/FU was over 100 times higher than that in DLD-1. With the analysis of expression profiles among 23 genes, we found that cIAP2 gene was up-regulated in DLD-1/FU compared with DLD-1 and other cell lines with low IC50. Next, the role of the cIAP2 gene was investigated for 5-FU resistance using RNA interference. The down-regulation of cIAP2 efficiently enhanced 5-FU sensitivity, the activation of caspase 3/7 and apoptosis under exposure to 5-FU. The immunohistochemistry of cIAP2 in cancer and corresponding normal tissues from colorectal cancer patients in stage III revealed that cIAP2 was more frequently expressed in cancer tissues than in normal tissues, and cIAP2-positive patients had a trend toward early recurrence after 5-FU-based chemotherapy. [Conclusion] IAPs are reported to be abnormally regulated and expressed in the majority of human malignancies at elevated levels. Among them, cIAP2 should be a possible therapeutic target in malignancies, especially in colorectal cancer. Citation Format: Koh Miura, Hideaki Karasawa, Wataru Fujibuchi, Shinobu Ohnuma, Michiaki Unno. cIAP2 as a therapeutic target in malignancies. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 2190. doi:10.1158/1538-7445.AM2013-2190
Reducing violence in severe mental illness
Authors: T. Steinert
Journal: BMJ (2001)

<h3>Abstract</h3> The process by which visual information is incorporated into the brain’s spatial framework to represent landmarks is poorly understood. Studies in humans and rodents suggest that retrosplenial cortex (RSC) plays a key role in these computations. We developed an RSC-dependent behavioral task in which head-fixed mice learned the spatial relationship between visual landmark cues and hidden reward locations. Two-photon imaging revealed that these cues served as dominant reference points for most task-active neurons and anchored the spatial code in RSC. Presenting the same environment but decoupled from mouse behavior degraded encoding fidelity. Analyzing visual and motor responses showed that landmark codes were the result of supralinear integration. Surprisingly, V1 axons recorded in RSC showed similar receptive fields. However, they were less modulated by task engagement, indicating that landmark representations in RSC are the result of local computations. Our data provide cellular- and network-level insight into how RSC represents landmarks.
Characteristics That Distinguish Difficult-to-Control Asthma in Inner-City Children
Authors: Jacqueline A. Pongracic, Rebecca A. Zabel, Denise C. Babineau, Edward M. Zoratti, George T. O'Connor, Robert A. Wood, Gurjit K. Khurana Hershey, Carolyn Kercsmar, Rebecca S. Gruchalla, Meyer Kattan, Stephen J. Teach, Samuel J. Arbes, William W. Busse, Peter J. Gergen, Alkis Togias, Cynthia Visness, Andrew H. Liu
Journal: Journal of Allergy and Clinical Immunology (2016)
A4.11 Syndecan-4 is an important player in regulating the WNT signalling pathway in articular cartilage
Authors: C Clarke, A Held, R Stange, G Nalesso, J Sherwood, U Hansen, L Godmann, F Echtermeyer, F Dell’Accio, T Pap, J Bertrand
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> The heparan sulfate proteoglycan syndecan-4 (Sdc4) is a regulator of various cartilage-related processes including osteoarthritis (OA). Blockade of Sdc4 signalling protects mice from cartilage degradation in experimentally induced OA. OA is characterised by matrix remodelling and hypertrophic differentiation of chondrocytes. Various signalling pathways including the WNT signalling pathway have been implicated to trigger this change of chondrocyte phenotype. Experiments investigating the effect of different WNT3a concentrations on chondrocytes have emphasised a complex dialogue between canonical and non-canonical WNT pathways. We hypothesise that Sdc4 controls the chondrocyte phenotype by specific modulation of WNT signalling pathways. <h3>Methods</h3> <i>In vitro</i> analyses were performed using neonatal wild type (wt) and Sdc4-/- chondrocytes, or blocking antibodies against Sdc4. The influence of WNT3a on glycosaminoglycan (GAG) production was analysed using alcian blue staining of micromass cultures. Expression of marker genes (e.g. aggrecan, collagen2, MMP13) was measured by quantitative RT-PCR. Effects of WNT3a on canonical and non canonical WNT signalling were analysed using Western Blot (ß-catenin and pCamKII) and luciferase reporter assay (TCF/Lef). <i>In vivo</i>relevance was investigated upon induction of OA using the DMM model. <h3>Results</h3> Micromass cultures revealed a higher basal GAG production by Sdc4-/- chondrocytes. WNT3a stimulation led to a decrease in GAG production in wt cells, which was absent in Sdc4-/- chondrocytes. qRT-PCR showed a 10x higher basal production of aggrecan and collagen2 in Sdc4-/- chondrocytes. WNT3a increased the expression of both genes in Sdc-4 -/-, whereas decreasing the expression in wt chondrocytes. MMP13 was significantly less expressed in Sdc4-/- chondrocytes and, unlike in wt cells, was not up regulated upon WNT3a stimulation. Western blot showed that ß-catenin is not up regulated upon stimulation with WNT3a in Sdc4-/- chondrocytes. LRP6 was less phosphorylated and TCF/Lef promotor was less activated upon WNT3a stimulation in Sdc4-/- chondrocytes. pCamKII was increased under basal conditions, but decreased upon WNT3a stimulation in Sdc4-/-. The same effects on canonical and non canonical WNT signalling upon WNT stimulation were obtained by using a blocking anti-Sdc-4 antibody. <i>In vivo</i> stainings confirmed <i>in vitro</i> results. <h3>Conclusion</h3> Sdc4 is a major regulator of cellular response to WNT signals through facilitating the induction of the canonical WNT signalling pathway. The blockade of Sdc4 protects from OA induced changes in chondrocyte phenotype by inhibiting WNT induced differentiation of chondrocytes.
Abstract P3-13-02: Safety and Efficacy of Zoledronic Acid Beyond 24 Months in Breast Cancer Patients
Authors: Y Suzuki, Y Saito, R Ogiya, R Oshitanai, M Terao, M Terada, T Morioka, B Tsuda, N Niikura, T Okamura, Y Tokuda
Journal: Cancer Research (2012)

Abstract Background: Bisphosphonate therapy has decreased the risk of skeletal complications associated with osteolytic bone lesions in patients with breast cancer and multiple myeloma. The large prospective studies have used 21 to 24 months of treatment. We studied the safety and efficacy of Zoledronic acid in a subset of patients who received therapy for more than 24 months. Patients and Methods: Patients who received Zoledronic acid were identified. Data on skeletal events and laboratory parameters were gathered by chart review. The treatment regimen is 4 mg of Zolendronic acid at 3- to 4-week intervals, and concurrent chemotherapy, hormonal therapy, and radiation therapy was included. Before approval of Zoledronic acid, we were using Pamidronate and Incadronate. Results: We used the Zoledronic acid in 221 patients from June 2006 until December 2011 (range, 1–69 times of administration). We analyzed 71 cases in which the treatment could be continued for more than 24 months (range, 24–69 times of administration). No significant calcium, phosphorus, electrolyte abnormalities were encountered. There were no significant differences between the long-term treatment patients with Zoledronic acid and all the other patients in the range of pain felt at the time of the bone metastasis diagnosis, or the bone metastases sites. In addition, by March 2012, more than 50% patients of long-term usage of Zoledronic acid had continued receiving treatment. And in all of the patients, as well, the most cited reason for discontinuing treatment was a disease progression, adverse effect was few. In long-term treatment patients, 4 cases of fractures and 2 cases of spinal compression were encountered. The median time until an SRE occurred was 37 months. There were fewer occurrences of SREs in our investigation than in the 12 months of a clinical trial conducted in Japan with Zoledronic acid and a placebo. As for adverse effects, BRONJ appeared in 4 (1.8%) out of a total of 221 cases, and in 3 (4.2%) at prolonged treatment patients. The other adverse effects were fever in 4 cases and fatigue in 2 cases. Conclusion: Prolonged treatment with Zoledronic acid seems to be well tolerated and should be studied in prospective, randomized studies to document prolonged skeletal efficacy and survival. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P3-13-02.
Observing Patients after Antibiotics Are Discontinued
Authors: Bruce F. Farber, David J. Cooper
Journal: New England Journal of Medicine (1995)

The editorial "The Internet and the Journal " ( June 22 issue) 1 addresses the pros and cons of electronic "publishing" of articles on the Internet.You mentioned abstracts in passing, but the specter of electronic publishing of abstracts raises even more serious questions.Any flaws in the proposal for electronic publication of articles would be magnified enormously for electronic abstract publication.The selection process for abstracts already has demonstrable shortcomings.One study found that abstracts frequently were never published, and if they were it was only after a long interval.The number of citations of abstracts (a measure of interest in their content) was not a predictor of subsequent successful publication. 2Subsequent analyses have expanded these observations. 3Negative abstract results were published less often as papers, 4 and even when publication did result, long delays were common. 5 The electronic publication of data in an abstract, even when they are published later as an article, can lead to the acceptance of flawed or preliminary information by the medical community long before the data have been subjected to critical peer review.The risk of disseminating this unvalidated information is obvious.
The Two-Sided Face of Antidepressants: The Impact of Their Use on Real-Life Affective Change during Mindfulness-Based Cognitive Therapy
Authors: Jindra Myrthe Bakker, Ritsaert Lieverse, Nicole Geschwind, Frenk Peeters, Inez Myin-Germeys, Marieke Wichers
Journal: Psychotherapy and Psychosomatics (2016)
THU0122 Multi-Biomarker Scores as Predictors of Response to Biologic Therapies in Rheumatoid Arthritis
Authors: A. Novikov, E. N. Alexandrova, A. N. Gerasimov, A. S. Avdeeva, G. V. Lukina, Y. A. Sigidin, T. V. Popkova, E. Y. Panasyuk, E. L. Nasonov
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> The prediction of individual response to biological treatment has become a major clinical challenge in RA. Recent studies have provided evidence that biomarkers may be identified predictive of the response to therapy with these agents<sup>1</sup>. <h3>Objectives</h3> To identify a candidate multi-biomarker score (MB) of response to infliximab (INF), rituximab (RTX) and tocilizumab (TCZ) therapies in RA. <h3>Methods</h3> The study cohort included 97 RA patients, 21 starting INF, 27 RTM and 42 TCZ therapies. After 24 weeks, the EULAR criteria were used to classify patients as responders or nonresponders. Good response was achieved by 22.7% for INF, 5.8% for RTM and 16.6% for TCZ. 4 antibodies (IgM RF, IgA RF, anti-CCP, AMCV), 3 inflammation markers (ESR, CRP, calprotectin), 3 markers of bone (sRANKL) and cartilage (COMP, MMP-3) metabolism, 27 cytokines (IL-1β,-1ra,-2,-4,-5,-6,-7,-8,-9,-10,-12,-13,-15, -17, basic FGF, eotaxin, G-CSF, GM-CSF, IFN-γ, IP-10, MCP-1, MIP-1α, MIP-1β, PDGF-BB, RANTES, TNF-α, VEGF) serum concentrationswere measured. Analysis of consistency and confidence as biomarkers of early RA was carried out by multivariate logistic regression. <h3>Results</h3> A multi-biomarker scores of response: to INF (MBINF) was calculated based on the concentrations of: IL-17,-12,-9, CRP (AUC 0,96; sensitivity 100%; specificity 75%; LR+ 4; LR- 0, cutoff=0,45); to RTM (MBRTM): VEGF, IL-1ra,-10, G-CSF, IgM RF (AUC 0,99; sensitivity 96%; specificity 99%; LR+ 96; LR- 0,01 cutoff=0,6); to TCZ (MBTCZ): MMP-3, VEGF, anti-CCP (AUC 0,85; sensitivity 80%; specificity 83%; LR+ 4,7; LR- 0,2, cutoff =1,27). <h3>Conclusions</h3> All candidate multi-biomarker scores of response to INF, RTX and TCZ therapies in RA demonstrated a good diagnostics performance. After accurate validation, this test could be used in clinical laboratory practice. <h3>References</h3> Simsek I. Predictors of Response to TNF Inhibitors in Rheumatoid Arthritis - Do We Have New Tools for Personalized Medicine? Bull NYU Hosp Jt Dis. 2012;70(3):187-90. <h3>Disclosure of Interest</h3> None Declared
Abstract 1600: A multiplexed marker-based algorithm for diagnosis of carcinoma of unknown primary using circulating tumor cells
Authors: Elizabeth M. Matthew, Lanlan Zhou, Namrata Vijayvergia, David T. Dicker, Karen S. Gustafson, Harry S. Cooper, Eric A. Ross, Bora Lim, Ramdane Harouaka, Si-Yang Zheng, Nicholas E. Lamparella, Joseph J. Drabick, Cristina I. Truica, Zhaohai Yang, Wafik S. El-Deiry
Journal: Cancer Research (2015)

Abstract Abstract: Real-time, single-cell multiplex immunophenotyping of circulating tumor cells (CTCs) is hypothesized to inform diagnosis of tissue of origin in patients with carcinoma of unknown primary (CUP). In 20 to 50% of CUP patients, the primary site remains unidentified, presenting a challenge for clinicians in diagnosis and treatment. Invasive tissue biopsy is the gold standard for diagnosis but improved methodology is needed. We developed a post-CellSearch CTC assay using multiplexed Q-dot or DyLight conjugated antibodies with the goal of detecting multiple markers in single cells within a CTC population. We adapted our approach to size-based CTC enrichment protocols for capturing CTCs and subsequent immunofluorescence (IF) using a minimal set of markers to predict the primary sites for common metastatic tumors. The carcinomas are diagnosed with cytokeratin 7 (CK7), cytokeratin 20 (CK20), thyroid transcription factor 1 (TTF-1), estrogen receptor (ER) or prostate-specific antigen (PSA) as the minimal set of informative markers. IF has been optimized in cultured tumor cells with individual antibodies, then with conjugated antibodies to form a multiplex antibody set. With IF, we evaluated antibodies specific to these 5 markers in lung, breast, colorectal, and prostate cancer cell lines and blood samples from metastatic prostate and breast cancer patients. Our technological advance provides a noninvasive, inexpensive, diagnostic blood test as an adjunct to routine tissue biopsy. Its further implementation requires prospective clinical testing. Citation Format: Elizabeth M. Matthew, Lanlan Zhou, Namrata Vijayvergia, David T. Dicker, Karen S. Gustafson, Harry S. Cooper, Eric A. Ross, Bora Lim, Ramdane Harouaka, Si-Yang Zheng, Nicholas E. Lamparella, Joseph J. Drabick, Cristina I. Truica, Zhaohai Yang, Wafik S. El-Deiry. A multiplexed marker-based algorithm for diagnosis of carcinoma of unknown primary using circulating tumor cells. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 1600. doi:10.1158/1538-7445.AM2015-1600